Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACT134
MIFTS: 56

Acute Liver Failure

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Acute Liver Failure

About this section

MalaCards integrated aliases for Acute Liver Failure:

Name: Acute Liver Failure 58 54 37
Fulminant Hepatic Failure 58 36 29 6
Acute Hepatic Failure 58 6
Hepatic Failure Fulminant 54
Liver Failure, Acute 71
Liver Failure Acute 54

Characteristics:

Orphanet epidemiological data:

58
acute liver failure
Prevalence: 1-5/10000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Metabolic diseases
Anatomical: Liver diseases Blood diseases Gastrointestinal diseases Bone diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare hepatic diseases


External Ids:

KEGG 36 H01712
MESH via Orphanet 44 D017114
ICD10 via Orphanet 33 K72.0
UMLS via Orphanet 72 C0162557
Orphanet 58 ORPHA90062
UMLS 71 C0162557
Sources

Summaries for Acute Liver Failure

About this section
KEGG : 36 Fulminant hepatic failure (FHF) is a life-threatening condition characterized by the rapid deterioration of liver functions and hepatic encephalopathy. FHF is with the basic definition of the onset of hepatic encephalopathy within 8 weeks of the appearance of the first symptoms like jaundice, fever, nausea, and vomiting. The prothrombin time is prolonged by 4-6 seconds or more. While the etiologies of FHF are multiple and varied, viral hepatitis is the most frequent cause. Around 40-60% of patients with FHF are thought to be due to some viral infection. The prognosis is dependent on several factors, including the underlying cause of liver failure. For instance, it is well known that the spontaneous recovery rates from FHF from such etiologies as hepatitis A and acetaminophen toxicity are high, whereas those same rates for other types of viral hepatitis and idiosyncratic drug reactions are quite low. Identification of the cause of FHF is important because some causes have specific treatment interventions or antidotes. Specific therapies include N-acetylcysteine for acetaminophen overdose, and acyclovir for herpesvirus infection. Different therapeutic options such as complete exchange blood transfusion, corticosteroids, and plasma pheresis, have been tried. However, the overall prognosis for patients with FHF is quite poor, with survival rates usually reported between 10% and 30% without liver transplantation.

MalaCards based summary : Acute Liver Failure, also known as fulminant hepatic failure, is related to hepatitis a and infantile liver failure syndrome 1. An important gene associated with Acute Liver Failure is RINT1 (RAD50 Interactor 1). The drugs Lamivudine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include Liver, brain and bone, and related phenotypes are increased intracranial pressure and seizures

Wikipedia : 74 Acute liver failure is the appearance of severe complications rapidly after the first signs (such as... more...

Sources

Related Diseases for Acute Liver Failure

About this section

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Acute Liver Failure

Diseases related to Acute Liver Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 649, show less)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 32.1 GPT F2 ALB
2 infantile liver failure syndrome 1 31.8 SLC17A5 GPT F2 ALB
3 paracetamol poisoning 30.9 GC F2
4 hepatitis e 30.6 GPT F2 ALB
5 wilson disease 30.4 GPT F2 ALB
6 hepatic coma 30.3 TSPO GPT F2 ALB
7 autoimmune hepatitis 30.3 SLC17A5 GPT F2 ALB
8 hepatorenal syndrome 30.3 GPT F2 ALB
9 fatty liver disease, nonalcoholic 1 30.2 SLC17A5 GPT
10 drug-induced hepatitis 30.2 GPT F2 ALB
11 exanthem 30.1 GPT F2 ALB
12 fatty liver disease 30.1 SLC17A5 GPT ALB
13 hellp syndrome 30.1 SLC17A5 GPT F2
14 dengue hemorrhagic fever 30.0 GPT F2 ALB
15 portal hypertension 30.0 GPT F2 ALB
16 scrub typhus 30.0 SLC17A5 GPT
17 metabolic acidosis 30.0 GPT F2 ALB
18 hepatitis d 30.0 GPT F2
19 cholestasis 29.9 SLC17A5 GPT F2 ALB
20 drug allergy 29.9 GPT ALB
21 inherited metabolic disorder 29.9 GPT F2 ALB
22 reye syndrome 29.9 GPT ALB
23 liver disease 29.8 SLC17A5 HGF GPT F2 ALB
24 tricuspid valve insufficiency 29.8 F2 ALB
25 acute kidney failure 29.8 HGF GPT F2 ALB
26 non-a-e hepatitis 29.8 F2 ALB
27 volvulus of midgut 29.8 GPT ALB
28 bilirubin metabolic disorder 29.8 SLC17A5 GPT F2 ALB
29 hepatic infarction 29.7 GPT F2 ALB
30 cholecystitis 29.7 GPT F2 ALB
31 bronchopneumonia 29.7 GPT ALB
32 sclerosing cholangitis 29.7 GPT F2 ALB
33 alcohol use disorder 29.7 SLC17A5 GPT ALB
34 granulomatous hepatitis 29.7 GPT ALB
35 acute kidney tubular necrosis 29.6 HGF ALB
36 cardiac tamponade 29.6 F2 ALB
37 splenic infarction 29.6 GPT F2 ALB
38 babesiosis 29.6 GPT ALB
39 ascending cholangitis 29.6 GPT F2 ALB
40 acute cystitis 29.5 GPT F2 ALB
41 mitral valve insufficiency 29.5 F2 ALB
42 pericardial effusion 29.5 GPT F2 ALB
43 syphilis 29.5 GPT F2 ALB
44 liver cirrhosis 29.5 SLC17A5 HGF GPT F2 ALB
45 cholangitis 29.4 SLC17A5 GPT F2 ALB
46 hepatitis b 29.4 SLC17A5 GPT FGL2 F2 ALB
47 hepatic tuberculosis 29.4 GPT F2 ALB
48 abdominal tuberculosis 29.4 GPT F2 ALB
49 bile duct disease 29.4 GPT F2 ALB
50 esophageal varix 29.4 GPT F2 ALB
51 anuria 29.4 GPT F2 ALB
52 primary biliary cirrhosis 29.4 SLC17A5 GPT F2 ALB
53 hypersplenism 29.4 GPT F2 ALB
54 hepatic encephalopathy 29.3 TSPO SLC17A5 GPT GC F2 ALB
55 viral hepatitis 29.3 SLC17A5 HGF GPT FGL2 F2 ALB
56 alpha-1-antitrypsin deficiency 29.3 GPT F2 ALB
57 typhoid fever 29.3 GPT F2 ALB
58 non-alcoholic steatohepatitis 29.3 HGF GPT ALB
59 blood coagulation disease 29.3 GPT F2 ALB
60 cholangitis, primary sclerosing 29.3 GPT F2 ALB
61 compartment syndrome 29.1 SLC17A5 GPT F2 ALB
62 peripheral nervous system disease 29.0 POLG GPT ALB
63 biliary atresia 29.0 HGF GPT F2 ALB
64 alcoholic hepatitis 28.9 SLC17A5 HGF GPT F2 ALB
65 obstructive jaundice 28.3 SLC17A5 HGF GPT F2 ALB
66 alcoholic liver cirrhosis 28.3 SLC17A5 HGF GPT F2 ALB
67 multiple sclerosis 27.9 TSPO POLG GC ALB
68 spinocerebellar ataxia, autosomal recessive 21 12.0
69 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.7
70 infantile liver failure syndrome 3 11.7
71 liver failure, infantile, transient 11.7
72 infantile liver failure syndrome 2 11.6
73 hepatitis 11.5
74 mitochondrial dna depletion syndrome 6 11.4
75 ruijs-aalfs syndrome 11.4
76 3-alpha hydroxyacyl-coa dehydrogenase deficiency 11.4
77 mitochondrial dna depletion syndrome 4a 11.2
78 encephalopathy 10.9
79 ocular motor apraxia 10.7
80 intracranial hypertension 10.7
81 brain edema 10.7
82 carbonic anhydrase va deficiency, hyperammonemia due to 10.6
83 fever-associated acute infantile liver failure syndrome 10.4 RINT1 NBAS
84 hemophagocytic lymphohistiocytosis 10.4
85 hypoglycemia 10.4
86 toxic shock syndrome 10.4
87 herpes simplex 10.3
88 respiratory failure 10.3
89 central nervous system origin vertigo 10.3 POLG F2
90 hepatoportal sclerosis 10.3 GPT F2
91 budd-chiari syndrome 10.3
92 hepatitis, fulminant viral 10.3
93 emphysematous cholecystitis 10.3 GPT F2
94 encephalopathy, progressive, with or without lipodystrophy 10.3
95 lymphoma 10.3
96 lactic acidosis 10.3
97 paraquat poisoning 10.3 SLC17A5 GPT
98 parenteral nutrition-associated cholestasis 10.2 SLC17A5 GPT
99 dengue disease 10.2
100 splenomegaly 10.2
101 b-cell lymphoma 10.2
102 exercise-induced malignant hyperthermia 10.2
103 mitochondrial dna depletion syndrome 5 10.2 POLG GPT
104 methotrexate toxicity 10.2 SLC17A5 GPT
105 aplastic anemia 10.2
106 dengue virus 10.2
107 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
108 disseminated intravascular coagulation 10.2
109 pancytopenia 10.2
110 thrombocytopenia 10.2
111 cytokine deficiency 10.2
112 rocky mountain spotted fever 10.2 SLC17A5 GPT
113 anterior spinal artery syndrome 10.2 FGL2 F2
114 hemochromatosis, type 1 10.2
115 acute pancreatitis 10.2
116 severe combined immunodeficiency 10.2
117 hemochromatosis, neonatal 10.1
118 bacterial infectious disease 10.1
119 substance abuse 10.1
120 kidney disease 10.1
121 congestive heart failure 10.1
122 chickenpox 10.1
123 mitochondrial disorders 10.1
124 48,xyyy 10.1
125 overgrowth syndrome 10.1
126 antipyrine metabolism 10.1 F2 ALB
127 cortical blindness 10.1 POLG F2
128 fournier gangrene 10.1 F2 ALB
129 dipetalonemiasis 10.1 GPT ALB
130 autoimmune disease 10.1
131 breast cancer 10.1
132 lymphoma, hodgkin, classic 10.1
133 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
134 deficiency anemia 10.1
135 dengue shock syndrome 10.1
136 hypophosphatemia 10.1
137 diffuse large b-cell lymphoma 10.1
138 neutropenia 10.1
139 amyloidosis 10.1
140 tyrosinemia 10.1
141 hypereosinophilic syndrome 10.1
142 heterophyiasis 10.1 GPT ALB
143 epidural abscess 10.1 F2 ALB
144 hypertensive encephalopathy 10.1 F2 ALB
145 mediastinitis 10.1 F2 ALB
146 galactosemia i 10.1
147 myeloma, multiple 10.1
148 stroke, ischemic 10.1
149 lymphoma, non-hodgkin, familial 10.1
150 hepatitis c virus 10.1
151 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.1
152 epidemic typhus 10.1
153 portal vein thrombosis 10.1
154 adult-onset still's disease 10.1
155 hepatitis c 10.1
156 leptospirosis 10.1
157 hemolytic anemia 10.1
158 t-cell lymphoblastic leukemia/lymphoma 10.1
159 neuroblastoma 10.1
160 leukemia, t-cell, chronic 10.1
161 intracranial embolism 10.1 F2 ALB
162 critical illness polyneuropathy 10.1 GPT ALB
163 buerger disease 10.1 HGF F2
164 active peptic ulcer disease 10.0 F2 ALB
165 pleural empyema 10.0 F2 ALB
166 heart aneurysm 10.0 GPT ALB
167 coronary aneurysm 10.0 GPT ALB
168 pyridoxine deficiency anemia 10.0 SLC17A5 GPT F2
169 hydrops of gallbladder 10.0 GPT ALB
170 hemorrhoid 10.0 F2 ALB
171 halothane hepatitis 10.0
172 ornithine transcarbamylase deficiency, hyperammonemia due to 10.0
173 leukemia, chronic myeloid 10.0
174 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
175 melanoma, cutaneous malignant 10 10.0
176 adult t-cell leukemia 10.0
177 autosomal recessive disease 10.0
178 lymphoproliferative syndrome 10.0
179 allergic hypersensitivity disease 10.0
180 leukemia 10.0
181 melanoma 10.0
182 ischemia 10.0
183 hypokalemia 10.0
184 peritonitis 10.0
185 myeloid leukemia 10.0
186 47,xyy 10.0
187 sickle cell disease 10.0
188 secondary hemophagocytic lymphohistiocytosis 10.0
189 cardiogenic shock 10.0
190 klatskin's tumor 10.0 GPT ALB
191 tricuspid valve disease 10.0 F2 ALB
192 intestinal perforation 10.0 GPT ALB
193 thrombophilia 10.0
194 gastritis 10.0
195 pustulosis of palm and sole 10.0
196 complement deficiency 10.0
197 psoriasis 10.0
198 mycobacterium xenopi 10.0
199 alcohol dependence 10.0
200 atrial standstill 1 10.0
201 colorectal cancer 10.0
202 leukemia, chronic lymphocytic 10.0
203 graves disease 1 10.0
204 ataxia and polyneuropathy, adult-onset 10.0
205 kala-azar 1 10.0
206 leukemia, acute lymphoblastic 10.0
207 aspergillosis 10.0
208 short stature, optic nerve atrophy, and pelger-huet anomaly 10.0
209 angiosarcoma 10.0
210 inflammatory bowel disease 10.0
211 small cell carcinoma 10.0
212 peripheral t-cell lymphoma 10.0
213 cardiac arrest 10.0
214 thrombosis 10.0
215 non-alcoholic fatty liver disease 10.0
216 diarrhea 10.0
217 gastroenteritis 10.0
218 pancreatitis 10.0
219 hyperthyroidism 10.0
220 myocarditis 10.0
221 mucormycosis 10.0
222 genital herpes 10.0
223 leishmaniasis 10.0
224 visceral leishmaniasis 10.0
225 urea cycle disorder 10.0
226 yellow fever 10.0
227 al amyloidosis 10.0
228 macrophage activation syndrome 10.0
229 neonatal herpes 10.0
230 short stature with optic atrophy and pelger-huët anomaly syndrome 10.0
231 chronic pain 10.0
232 hypotonia 10.0
233 tremor 10.0
234 disorder of copper metabolism 10.0
235 thrombophlebitis 10.0 F2 ALB
236 danubian endemic familial nephropathy 9.9 F2 ALB
237 autoimmune disease of urogenital tract 9.9 FGL2 ALB
238 graft-versus-host disease 9.9
239 graves' disease 9.9
240 hyperuricemia 9.9
241 ankylosing spondylitis 1 9.9 GPT F2 ALB
242 splenic abscess 9.9 GPT F2 ALB
243 acalculous cholecystitis 9.9 GPT F2 ALB
244 acetaminophen metabolism 9.9
245 hepatocellular carcinoma 9.9
246 cleft palate, isolated 9.9
247 fibrosis of extraocular muscles, congenital, 1 9.9
248 intussusception 9.9
249 pelger-huet anomaly 9.9
250 fructose intolerance, hereditary 9.9
251 niemann-pick disease, type c1 9.9
252 3-methylglutaconic aciduria, type iii 9.9
253 patent ductus venosus 9.9
254 leukemia, acute myeloid 9.9
255 sickle cell anemia 9.9
256 malaria 9.9
257 myelodysplastic syndrome 9.9
258 juvenile arthritis 9.9
259 follicular lymphoma 9.9
260 infective endocarditis 9.9
261 colitis 9.9
262 mitochondrial dna depletion syndrome 9.9
263 hepatic veno-occlusive disease 9.9
264 endocarditis 9.9
265 prolymphocytic leukemia 9.9
266 pre-eclampsia 9.9
267 adult respiratory distress syndrome 9.9
268 pulmonary edema 9.9
269 visual epilepsy 9.9
270 hemosiderosis 9.9
271 acute leukemia 9.9
272 porphyria 9.9
273 eclampsia 9.9
274 niemann-pick disease 9.9
275 candidiasis 9.9
276 angioedema 9.9
277 duodenal ulcer 9.9
278 constipation 9.9
279 colon adenocarcinoma 9.9
280 pulmonary tuberculosis 9.9
281 purpura 9.9
282 myopathy 9.9
283 acquired immunodeficiency syndrome 9.9
284 juvenile rheumatoid arthritis 9.9
285 thyroiditis 9.9
286 influenza 9.9
287 ulcerative colitis 9.9
288 subacute delirium 9.9
289 rubella 9.9
290 meningitis 9.9
291 encephalitis 9.9
292 polyarteritis nodosa 9.9
293 drug reaction with eosinophilia and systemic symptoms 9.9
294 systemic onset juvenile idiopathic arthritis 9.9
295 seizure disorder 9.9
296 rare hereditary hemochromatosis 9.9
297 acute cholangitis 9.9 GPT F2 ALB
298 paralytic ileus 9.9 GPT F2 ALB
299 common bile duct disease 9.9 GPT F2 ALB
300 pyuria 9.9 GPT F2 ALB
301 cecal disease 9.9 GPT F2 ALB
302 aspiration pneumonia 9.9 GPT F2 ALB
303 plasma protein metabolism disease 9.9 GPT F2 ALB
304 pericardium disease 9.8 GPT F2 ALB
305 pulmonary artery disease 9.8 GPT F2 ALB
306 splenic disease 9.8 GPT F2 ALB
307 hepatic vascular disease 9.8 GPT F2 ALB
308 metal metabolism disorder 9.8 GPT F2 ALB
309 vein disease 9.8 GPT F2 ALB
310 autoimmune disease of gastrointestinal tract 9.8 GPT F2 ALB
311 acropectorovertebral dysplasia 9.8
312 cardiac conduction defect 9.8
313 hypercholesterolemia, familial, 1 9.8
314 yellow nail syndrome 9.8
315 melanoma, uveal 9.8
316 prostate cancer 9.8
317 dowling-degos disease 1 9.8
318 sarcoidosis 1 9.8
319 thrombophilia due to activated protein c resistance 9.8
320 ascites, chylous 9.8
321 celiac disease 1 9.8
322 hyperornithinemia-hyperammonemia-homocitrullinuria syndrome 9.8
323 immunoerythromyeloid hypoplasia 9.8
324 mycosis fungoides 9.8
325 pancreatic cancer 9.8
326 reticular dysgenesis 9.8
327 kearns-sayre syndrome 9.8
328 wilms tumor 5 9.8
329 propionic acidemia 9.8
330 phelan-mcdermid syndrome 9.8
331 gastrointestinal stromal tumor 9.8
332 major depressive disorder 9.8
333 antithrombin iii deficiency 9.8
334 peripartum cardiomyopathy 9.8
335 leptin deficiency or dysfunction 9.8
336 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.8
337 mitochondrial dna depletion syndrome 16 9.8
338 livedoid vasculitis 9.8
339 autoimmune polyendocrine syndrome type 1 9.8
340 epstein-barr virus hepatitis 9.8
341 extrapulmonary tuberculosis 9.8
342 zollinger-ellison syndrome 9.8
343 cutaneous t cell lymphoma 9.8
344 hereditary lymphedema i 9.8
345 polycystic kidney disease 9.8
346 malignant hypertension 9.8
347 lepromatous leprosy 9.8
348 q fever 9.8
349 diphtheria 9.8
350 constrictive pericarditis 9.8
351 hemopericardium 9.8
352 oligohydramnios 9.8
353 chronic progressive external ophthalmoplegia 9.8
354 urethritis 9.8
355 peptic esophagitis 9.8
356 autoimmune polyendocrine syndrome 9.8
357 plasmodium falciparum malaria 9.8
358 panniculitis 9.8
359 mental depression 9.8
360 pericarditis 9.8
361 opiate dependence 9.8
362 transitional cell carcinoma 9.8
363 liver angiosarcoma 9.8
364 idiopathic interstitial pneumonia 9.8
365 chronic granulomatous disease 9.8
366 breast adenocarcinoma 9.8
367 choriocarcinoma 9.8
368 secondary syphilis 9.8
369 uremia 9.8
370 infertility 9.8
371 colonic disease 9.8
372 lung oat cell carcinoma 9.8
373 impetigo 9.8
374 herpes zoster 9.8
375 measles 9.8
376 liver lymphoma 9.8
377 amebiasis 9.8
378 alopecia 9.8
379 acute ackee fruit intoxication 9.8
380 congenital rubella 9.8
381 exfoliative dermatitis 9.8
382 ornithinemia 9.8
383 stevens-johnson syndrome/toxic epidermal necrolysis 9.8
384 cryptogenic cirrhosis 9.8
385 depression 9.8
386 dysphagia 9.8
387 head injury 9.8
388 headache 9.8
389 epithelioid hemangioendothelioma 9.8
390 systemic epstein-barr virus-positive t-cell lymphoproliferative disease of childhood 9.8
391 autoimmune hepatitis type 2 9.8
392 cocaine intoxication 9.8
393 nodular lymphocyte predominant hodgkin lymphoma 9.8
394 refractory anemia 9.8
395 blood platelet disease 9.8 GPT F2 ALB
396 schistosomiasis 9.8 GPT F2 ALB
397 fascioliasis 9.8 SLC17A5 GPT ALB
398 biliary tract disease 9.8 GPT F2 ALB
399 familial hypercholesterolemia 9.8 GPT F2 ALB
400 mineral metabolism disease 9.8 GPT GC ALB
401 pharyngitis 9.7 GPT ALB
402 neurofibromatosis, type ii 9.7
403 diabetes insipidus, nephrogenic, autosomal 9.7
404 ovarian cancer 9.7
405 multiple acyl-coa dehydrogenase deficiency 9.7
406 myelofibrosis 9.7
407 polycythemia vera 9.7
408 thymoma, familial 9.7
409 membranous nephropathy 9.7
410 alacrima, achalasia, and mental retardation syndrome 9.7
411 japanese spotted fever 9.7
412 coronavirus infectious disease 9.7
413 cholelithiasis 9.7
414 methemoglobinemia 9.7
415 gastric ulcer 9.7
416 spotted fever 9.7
417 chlamydia 9.7
418 tetanus 9.7
419 pyelonephritis 9.7
420 goiter 9.7
421 thyroid crisis 9.7
422 endometriosis 9.7
423 glomerulonephritis 9.7
424 thymoma 9.7
425 thymic carcinoma 9.7
426 histiocytosis 9.7
427 rapidly progressive glomerulonephritis 9.7
428 polycythemia 9.7
429 peliosis hepatis 9.7
430 diabetes insipidus 9.7
431 anca-associated vasculitis 9.7
432 chronic graft versus host disease 9.7
433 mirizzi syndrome 9.7
434 cerebral atrophy 9.7
435 acyl-coa dehydrogenase deficiency 9.7
436 pauci-immune glomerulonephritis 9.7
437 pfeiffer syndrome 9.7
438 burkitt lymphoma 9.7
439 alagille syndrome 1 9.7
440 congenital anomalies of kidney and urinary tract 2 9.7
441 renal cell carcinoma, nonpapillary 9.7
442 hypertriglyceridemia, familial 9.7
443 keratitis, hereditary 9.7
444 systemic lupus erythematosus 9.7
445 optic atrophy 1 9.7
446 osteoporosis 9.7
447 porphyria, acute intermittent 9.7
448 porphyria cutanea tarda 9.7
449 pulmonary fibrosis, idiopathic 9.7
450 pulmonary hypertension, primary, 1 9.7
451 small cell cancer of the lung 9.7
452 thrombocytopenic purpura, autoimmune 9.7
453 thrombophilia due to thrombin defect 9.7
454 varicose veins 9.7
455 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
456 acyl-coa dehydrogenase, medium-chain, deficiency of 9.7
457 alstrom syndrome 9.7
458 anemia, autoimmune hemolytic 9.7
459 arachnoid cysts, intracranial 9.7
460 ataxia-telangiectasia 9.7
461 bronchomalacia 9.7
462 lung cancer 9.7
463 citrullinemia, classic 9.7
464 schopf-schulz-passarge syndrome 9.7
465 factor x deficiency 9.7
466 visceral steatosis, congenital 9.7
467 3-hydroxyacyl-coa dehydrogenase deficiency 9.7
468 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
469 immune deficiency disease 9.7
470 leprosy 3 9.7
471 dihydrolipoamide dehydrogenase deficiency 9.7
472 mitochondrial dna depletion syndrome 3 9.7
473 proteasome-associated autoinflammatory syndrome 1 9.7
474 orotic aciduria 9.7
475 osteogenic sarcoma 9.7
476 phosphoenolpyruvate carboxykinase deficiency, cytosolic 9.7
477 autoimmune polyendocrine syndrome, type ii 9.7
478 insulin-like growth factor i 9.7
479 tyrosinemia, type i 9.7
480 sarcoma, synovial 9.7
481 glycerol kinase deficiency 9.7
482 prostatic hyperplasia, benign 9.7
483 yemenite deaf-blind hypopigmentation syndrome 9.7
484 xanthomatosis 9.7
485 citrullinemia, type ii, adult-onset 9.7
486 ventricular fibrillation, paroxysmal familial, 1 9.7
487 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
488 body mass index quantitative trait locus 1 9.7
489 anorexia nervosa 9.7
490 pulmonary disease, chronic obstructive 9.7
491 mycobacterium tuberculosis 1 9.7
492 severe cutaneous adverse reaction 9.7
493 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 9.7
494 bone mineral density quantitative trait locus 8 9.7
495 congenital disorder of glycosylation, type in 9.7
496 premature ovarian failure 7 9.7
497 fanconi renotubular syndrome 2 9.7
498 bone mineral density quantitative trait locus 15 9.7
499 hypogonadotropic hypogonadism 15 with or without anosmia 9.7
500 congenital disorder of deglycosylation 9.7
501 interstitial lung and liver disease 9.7
502 cholangiocarcinoma 9.7
503 pulmonary hypertension 9.7
504 bacterial sepsis 9.7
505 invasive aspergillosis 9.7
506 erythema multiforme 9.7
507 hyperphosphatemia 9.7
508 endemic typhus 9.7
509 exanthema subitum 9.7
510 anaplastic large cell lymphoma 9.7
511 atrioventricular block 9.7
512 ectopic cushing syndrome 9.7
513 aortic dissection 9.7
514 common cold 9.7
515 gastric lymphoma 9.7
516 meningoencephalitis 9.7
517 glucose intolerance 9.7
518 fanconi syndrome 9.7
519 thrombotic thrombocytopenic purpura 9.7
520 brucellosis 9.7
521 prostatic hypertrophy 9.7
522 sarcoma 9.7
523 hypoparathyroidism 9.7
524 pneumocystosis 9.7
525 megacolon 9.7
526 heart disease 9.7
527 nephrotic syndrome 9.7
528 esophagitis 9.7
529 conn's syndrome 9.7
530 aseptic meningitis 9.7
531 telangiectasis 9.7
532 dilated cardiomyopathy 9.7
533 pure red-cell aplasia 9.7
534 beriberi 9.7
535 polyneuropathy 9.7
536 hypothyroidism 9.7
537 papilledema 9.7
538 methylmalonic acidemia 9.7
539 urticaria 9.7
540 lymphadenitis 9.7
541 neuroendocrine tumor 9.7
542 vascular cancer 9.7
543 toxic megacolon 9.7
544 vascular disease 9.7
545 neuroendocrine carcinoma 9.7
546 status epilepticus 9.7
547 mononeuritis multiplex 9.7
548 rectum cancer 9.7
549 post-traumatic stress disorder 9.7
550 chronic mucocutaneous candidiasis 9.7
551 hemorrhagic disease 9.7
552 neonatal jaundice 9.7
553 wernicke encephalopathy 9.7
554 protein s deficiency 9.7
555 agammaglobulinemia 9.7
556 hairy cell leukemia 9.7
557 glucosephosphate dehydrogenase deficiency 9.7
558 prostatic adenoma 9.7
559 adenocarcinoma 9.7
560 breast ductal carcinoma 9.7
561 lipid metabolism disorder 9.7
562 rhabdomyosarcoma 9.7
563 mood disorder 9.7
564 plague 9.7
565 mixed connective tissue disease 9.7
566 skin disease 9.7
567 gastric adenocarcinoma 9.7
568 pulmonary fibrosis 9.7
569 arthropathy 9.7
570 merkel cell carcinoma 9.7
571 restrictive cardiomyopathy 9.7
572 blood group incompatibility 9.7
573 mutism 9.7
574 hyperglycemia 9.7
575 spindle cell sarcoma 9.7
576 amelanotic melanoma 9.7
577 intrahepatic cholangiocarcinoma 9.7
578 chronic inflammatory demyelinating polyradiculoneuropathy 9.7
579 demyelinating polyneuropathy 9.7
580 acute stress disorder 9.7
581 connective tissue disease 9.7
582 mitochondrial metabolism disease 9.7
583 placenta disease 9.7
584 end stage renal disease 9.7
585 chronic kidney disease 9.7
586 ileus 9.7
587 lung disease 9.7
588 monocytic leukemia 9.7
589 sezary's disease 9.7
590 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.7
591 nervous system disease 9.7
592 vasculitis 9.7
593 hodgkin's lymphoma, mixed cellularity 9.7
594 neuropathy 9.7
595 erythema infectiosum 9.7
596 crohn's disease 9.7
597 lupus erythematosus 9.7
598 hepatopulmonary syndrome 9.7
599 gas gangrene 9.7
600 homocystinuria 9.7
601 diabetes mellitus 9.7
602 exophthalmos 9.7
603 pulmonary embolism 9.7
604 miliary tuberculosis 9.7
605 muscular dystrophy 9.7
606 substance dependence 9.7
607 mpv17-related mitochondrial dna maintenance defect 9.7
608 medium-chain acyl-coenzyme a dehydrogenase deficiency 9.7
609 polg-related disorders 9.7
610 amyloidosis aa 9.7
611 broken heart syndrome 9.7
612 congenital hepatic fibrosis 9.7
613 hansen's disease 9.7
614 hemangioendothelioma 9.7
615 herpes simplex encephalitis 9.7
616 human t-cell leukemia virus type 1 9.7
617 mycobacterium kansasii 9.7
618 pepck 1 deficiency 9.7
619 periodontal ehlers-danlos syndrome 9.7
620 polymyositis 9.7
621 t-cell prolymphocytic leukemia 9.7
622 t-cell/histiocyte rich large b cell lymphoma 9.7
623 ngly1-congenital disorder of deglycosylation 9.7
624 brain injury 9.7
625 cerebral beriberi 9.7
626 cerebral hypoxia 9.7
627 cytomegalovirus infection 9.7
628 hypoxia 9.7
629 traumatic brain injury 9.7
630 posttransplant acute limbic encephalitis 9.7
631 b-cell non-hodgkin lymphoma 9.7
632 systemic autoimmune disease 9.7
633 cerebrofacial arteriovenous metameric syndrome 9.7
634 rapidly involuting congenital hemangioma 9.7
635 pulmonary arterial hypertension associated with portal hypertension 9.7
636 acute sensory ataxic neuropathy 9.7
637 erythema multiforme major 9.7
638 ethylene glycol poisoning 9.7
639 pik3ca-related overgrowth syndrome 9.7
640 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.7
641 thrombotic microangiopathy 9.7
642 red cell aplasia 9.7
643 thyroid carcinoma 9.7
644 lipoprotein quantitative trait locus 9.7 GPT F2 ALB
645 inherited blood coagulation disease 9.7 F2 ALB
646 kwashiorkor 9.6 SLC17A5 GPT F2 ALB
647 choledocholithiasis 9.6 SLC17A5 GPT F2 ALB
648 glycogen storage disease 9.4 SLC17A5 HGF ALB
649 analbuminemia 9.2 SLC17A5 GPT GC F2 ALB

Graphical network of the top 20 diseases related to Acute Liver Failure:



Diseases related to Acute Liver Failure
Sources

Symptoms & Phenotypes for Acute Liver Failure

About this section

Human phenotypes related to Acute Liver Failure:

58 (showing 50, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 increased intracranial pressure 58 Occasional (29-5%)
2 seizures 58 Occasional (29-5%)
3 vomiting 58 Frequent (79-30%)
4 fever 58 Occasional (29-5%)
5 hypoglycemia 58 Frequent (79-30%)
6 ataxia 58 Occasional (29-5%)
7 skin rash 58 Occasional (29-5%)
8 slurred speech 58 Frequent (79-30%)
9 hepatitis 58 Very frequent (99-80%)
10 gastrointestinal hemorrhage 58 Occasional (29-5%)
11 abnormal pattern of respiration 58 Frequent (79-30%)
12 elevated hepatic transaminase 58 Very frequent (99-80%)
13 depressivity 58 Occasional (29-5%)
14 thrombocytopenia 58 Frequent (79-30%)
15 jaundice 58 Very frequent (99-80%)
16 bruising susceptibility 58 Frequent (79-30%)
17 intracranial hemorrhage 58 Occasional (29-5%)
18 hyperammonemia 58 Frequent (79-30%)
19 abnormal bleeding 58 Occasional (29-5%)
20 prolonged prothrombin time 58 Frequent (79-30%)
21 encephalopathy 58 Occasional (29-5%)
22 hypotension 58 Frequent (79-30%)
23 diarrhea 58 Frequent (79-30%)
24 confusion 58 Frequent (79-30%)
25 pain insensitivity 58 Occasional (29-5%)
26 coma 58 Occasional (29-5%)
27 adrenal insufficiency 58 Frequent (79-30%)
28 acute kidney injury 58 Occasional (29-5%)
29 drowsiness 58 Frequent (79-30%)
30 deep venous thrombosis 58 Occasional (29-5%)
31 hyperventilation 58 Occasional (29-5%)
32 agitation 58 Frequent (79-30%)
33 incoordination 58 Occasional (29-5%)
34 acidosis 58 Occasional (29-5%)
35 cerebral edema 58 Occasional (29-5%)
36 functional respiratory abnormality 58 Frequent (79-30%)
37 nausea 58 Frequent (79-30%)
38 mood changes 58 Frequent (79-30%)
39 hepatic necrosis 58 Frequent (79-30%)
40 abnormality of the coagulation cascade 58 Frequent (79-30%)
41 hepatocellular necrosis 58 Very frequent (99-80%)
42 reduced factor vii activity 58 Frequent (79-30%)
43 hepatic periportal necrosis 58 Frequent (79-30%)
44 hypocapnia 58 Occasional (29-5%)
45 increased factor viii activity 58 Frequent (79-30%)
46 shock 58 Occasional (29-5%)
47 reduced factor x activity 58 Frequent (79-30%)
48 reduced coagulation factor v activity 58 Frequent (79-30%)
49 euphoria 58 Occasional (29-5%)
50 alkalosis 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Acute Liver Failure:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ALB F2 FGL2 GC HGF NBAS
2 homeostasis/metabolism MP:0005376 9.61 ALB F2 FGL2 GC NBAS POLG
3 mortality/aging MP:0010768 9.28 ALB F2 FGL2 HGF NBAS POLG
Sources

Drugs & Therapeutics for Acute Liver Failure

About this section

Drugs for Acute Liver Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 184, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
rituximab Approved Phase 4 174722-31-7 10201696
4
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
5
Norepinephrine Approved Phase 4 51-41-2 439260
6
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Lactulose Approved Phase 4 4618-18-2 11333
9
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
10
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
11 Neurotransmitter Agents Phase 4
12 N-Methylaspartate Phase 4
13 Reverse Transcriptase Inhibitors Phase 4
14 Anti-Retroviral Agents Phase 4
15 Anti-HIV Agents Phase 4
16 Gastrointestinal Agents Phase 4
17 Antibiotics, Antitubercular Phase 4
18 Vaccines Phase 4
19 Laxatives Phase 4
20 Cathartics Phase 4
21 Polyethylene glycol 3350 Phase 4
22 Pharmaceutical Solutions Phase 4
23
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
24
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
25
Lenograstim Approved, Investigational Phase 3 135968-09-1
26
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
27
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
28
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
29
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
30
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
31
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
32
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
33
Sodium citrate Approved, Investigational Phase 3 68-04-2
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
35 Molgramostim Investigational Phase 3 99283-10-0
36 Hypoglycemic Agents Phase 3
37 Adjuvants, Immunologic Phase 3
38 Immunologic Factors Phase 3
39 Antimetabolites Phase 3
40 Dermatologic Agents Phase 3
41 Hematinics Phase 3
42 Epoetin alfa Phase 3 113427-24-0
43 Immunosuppressive Agents Phase 3
44 Antifungal Agents Phase 3
45 Cyclosporins Phase 3
46 Calcineurin Inhibitors Phase 3
47 Antirheumatic Agents Phase 3
48 diuretics Phase 3
49 Vasoconstrictor Agents Phase 3
50 Hemostatics Phase 3
51 Antihypertensive Agents Phase 3
52 Chelating Agents Phase 3
53 Anticoagulants Phase 3
54 Calcium, Dietary Phase 3
55 Vitamins Phase 3
56 calcium heparin Phase 3
57 Fibrinolytic Agents Phase 3
58 Citrate Phase 3
59
Calcium Nutraceutical Phase 3 7440-70-2 271
60
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
61
Phenylacetic acid Approved Phase 2 103-82-2 999
62
Pentoxifylline Approved, Investigational Phase 1, Phase 2 6493-05-6 4740
63
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
64
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
65
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
66
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
67 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
68
Alprostadil Approved, Investigational Phase 1, Phase 2 745-65-3 149351 5280723
69
Ursodeoxycholic acid Approved, Investigational Phase 1, Phase 2 128-13-2 31401
70
glycyrrhizin Approved, Experimental Phase 1, Phase 2 1405-86-3 3495
71
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
72
Acetaminophen Approved Phase 1, Phase 2 103-90-2 1983
73
Cysteine Approved, Nutraceutical Phase 1, Phase 2 52-90-4 5862
74
Taurine Approved, Nutraceutical Phase 1, Phase 2 107-35-7 1123
75
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
76
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
77 Mitogens Phase 1, Phase 2
78 Ophthalmic Solutions Phase 2
79 Hormones Phase 1, Phase 2
80 Methylprednisolone Acetate Phase 1, Phase 2
81 Antineoplastic Agents, Hormonal Phase 1, Phase 2
82 Antiemetics Phase 1, Phase 2
83 Hormone Antagonists Phase 1, Phase 2
84 Neuroprotective Agents Phase 1, Phase 2
85 glucocorticoids Phase 1, Phase 2
86 Anti-Inflammatory Agents Phase 1, Phase 2
87 Adrenergic beta-Antagonists Phase 2
88 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
89 Protective Agents Phase 1, Phase 2
90 Respiratory System Agents Phase 1, Phase 2
91 Antidotes Phase 1, Phase 2
92 Antioxidants Phase 1, Phase 2
93 Expectorants Phase 1, Phase 2
94 Antiviral Agents Phase 1, Phase 2
95 N-monoacetylcystine Phase 1, Phase 2
96 Analgesics, Non-Narcotic Phase 1, Phase 2
97 Analgesics Phase 1, Phase 2
98 Antipyretics Phase 1, Phase 2
99
Histamine Approved, Investigational 51-45-6 774
100
Chlorpheniramine Approved 132-22-9, 113-92-8 2725
101
Cocaine Approved, Illicit 50-36-2 446220 5760
102
Saxagliptin Approved 361442-04-8 11243969
103
Clopidogrel Approved 113665-84-2, 120202-66-6 60606
104
Ticagrelor Approved 274693-27-5 9871419
105
Menthol Approved 2216-51-5 16666
106
Adefovir dipivoxil Approved, Investigational 142340-99-6 60871
107
Dinoprostone Approved 363-24-6 5280360
108
Edetic Acid Approved, Vet_approved 60-00-4, 62-33-9 6049
109
Iron Approved, Experimental 15438-31-0, 7439-89-6 27284 23925
110
Pentetic acid Approved 67-43-6
111
Chromium Approved 7440-47-3 27668
112
Sorafenib Approved, Investigational 284461-73-0 216239 406563
113
Sunitinib Approved, Investigational 557795-19-4, 341031-54-7 5329102